OKYO Pharma
OKYO
7 hedge funds and large institutions have $2.63M invested in OKYO Pharma in 2025 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 2 closing their positions.
123% more capital invested
Capital invested by funds: $1.18M → $2.63M (+$1.45M)
3.1% more ownership
Funds ownership: 3.03% → 6.12% (+3.1%)
0% more funds holding
Funds holding: 7 → 7 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DIG
Dauntless Investment Group
Etna,
New Hampshire
|
+$2.38M |
| 2 |
FIA
FNY Investment Advisers
New York
|
+$23.9K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$7.98K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barclays
London,
United Kingdom
|
-$1.11M |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$3.45K |
| 3 |
Renaissance Technologies
New York
|
-$3.06K |
OKYO Hedge Fund Activity: Q1 2025 in Review
7 of the 7,475 institutional investors tracked by Wall St. Rank reported a position in OKYO Pharma (OKYO) for Q1 2025, worth a combined $2.63M — up 123% from $1.18M a quarter earlier.
Fund positioning in OKYO was balanced in Q1 2025: 2 funds opened new positions, 2 closed out, 1 added to existing stakes and 1 trimmed.
The largest buyer was Dauntless Investment Group, opening a new position worth an estimated $2.38M. The largest seller was Barclays, exiting entirely with an estimated $1.11M sold.
- 7 institutional investors held OKYO Pharma (OKYO) as of Q1 2025, unchanged from Q4 2024.
- Funds reported $2.63M of OKYO Pharma stock for Q1 2025, up 123% quarter-over-quarter.
- 2 funds opened new OKYO Pharma positions in Q1 2025 and 2 closed out, a net change of 0 holders.
- The largest OKYO Pharma buyer in Q1 2025 was Dauntless Investment Group, an estimated $2.38M added.
- The largest OKYO Pharma seller in Q1 2025 was Barclays, an estimated $1.11M sold.
Based on aggregated 13F filings for Q1 2025.